This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectranetics Achieves Fourth Quarter Revenue Of $36.8 Million

13% Increase Over Q4 2011 Provides Outlook for 2013

COLORADO SPRINGS, Colo., Feb. 21, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the three and twelve months ended December 31, 2012. Highlights of the quarter (all compared with the quarter ended December 31, 2011) include:
  • Lead Management revenue growth of 29%, 30% on a constant currency basis 1
  • Vascular Intervention revenue growth of 5%, 6% on a constant currency basis, led by U.S. peripheral atherectomy growth of 15%
  • U.S. revenue increased 14% to $30.8 million
  • International revenue increased 8% to $5.9 million, 11% growth on a constant currency basis

"The fourth quarter of 2012 marks our fifth consecutive quarter of double digit revenue growth on a constant currency basis," said President and Chief Executive Officer, Scott Drake. "We set the goal more than a year ago to be a reliable, profitable double digit growth company—and in 2012, we have cleared this bar. As we look forward to 2013, we have reason to be excited about our prospects—our core markets are growing in the range of 10% and we are gaining share. We are providing our outlook for 2013, which anticipates continued success. Over the long term, we are striving to drive further revenue acceleration and continued margin expansion, which will culminate in meaningful operating leverage over time."

Net income for the fourth quarter of 2012 was $673,000, or $0.02 per diluted share, compared with net income of $355,000, or $0.01 per diluted share, for the fourth quarter of 2011. Non-GAAP adjusted net income for the fourth quarter of 2012 was $984,000, or $0.03 per diluted share, and for the fourth quarter of 2011 was $1.3 million, or $0.04 per diluted share. Non-GAAP adjusted net income excludes special items described later in this release under the heading "Reconciliation of Non-GAAP Financial Measures."
1Constant currency is a non-GAAP financial measure. See "Reconciliation of Non-GAAP Financial Measures" later in this release.

2012 Financial Results

Revenue for the twelve months ended December 31, 2012 rose 10% (11% on a constant currency basis) to $140.3 million, from $127.3 million in 2011. Vascular Intervention revenue increased 8% (9% on a constant currency basis) to $67.3 million; Lead Management revenue increased 19% (20% on a constant currency basis) to $55.2 million; and laser system, service and other revenue decreased 4%, both on an as reported and constant currency basis, to $17.8 million.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.69 -0.59%
FB $119.49 1.43%
GOOG $711.11 1.40%
TSLA $214.93 1.61%
YHOO $37.23 0.79%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs